Suppr超能文献

酪蛋白中性pH值最能解释吡嗪酰胺对C3HeB/FeJ小鼠结核病的选择性无活性。

Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum.

作者信息

Lanoix Jean-Philippe, Ioerger Thomas, Ormond Aimee, Kaya Firat, Sacchettini James, Dartois Véronique, Nuermberger Eric

机构信息

Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA INSERM U1088, Amiens, France.

Department of Computer Science, Texas A&M University, College Station, Texas, USA.

出版信息

Antimicrob Agents Chemother. 2015 Nov 16;60(2):735-43. doi: 10.1128/AAC.01370-15. Print 2016 Feb.

Abstract

Pyrazinamide (PZA) is one of only two sterilizing drugs in the first-line antituberculosis regimen. Its activity is strongly pH dependent; the MIC changes by several orders of magnitude over a range of pH values that may be encountered in various in vivo compartments. We recently reported selective inactivity of PZA in a subset of C3HeB/FeJ mice with large caseous lung lesions. In the present study, we evaluated whether such inactivity was explained by poor penetration of PZA into such lesions or selection of drug-resistant mutants. Despite demonstrating similar dose-proportional PZA exposures in plasma, epithelial lining fluid, and lung lesions, no dose response was observed in a subset of C3HeB/FeJ mice with the highest CFU burden. Although PZA-resistant mutants eventually replaced the susceptible bacilli in BALB/c mice and in C3HeB/FeJ mice with low total CFU burdens, they never exceeded 1% of the total population in nonresponding C3HeB/FeJ mice. The selective inactivity of PZA in large caseous lesions of C3HeB/FeJ mice is best explained by the neutral pH of liquefying caseum.

摘要

吡嗪酰胺(PZA)是一线抗结核治疗方案中仅有的两种杀菌药物之一。其活性强烈依赖于pH值;在不同体内腔室可能遇到的一系列pH值范围内,其最低抑菌浓度(MIC)会改变几个数量级。我们最近报道,PZA在一部分患有大量干酪样肺损伤的C3HeB/FeJ小鼠中表现出选择性无活性。在本研究中,我们评估了这种无活性是由于PZA难以渗透到此类损伤中,还是由于耐药突变体的选择所致。尽管在血浆、上皮衬液和肺损伤中PZA的暴露呈现出相似的剂量比例关系,但在一部分CFU负荷最高的C3HeB/FeJ小鼠中未观察到剂量反应。虽然在BALB/c小鼠和总CFU负荷较低的C3HeB/FeJ小鼠中,耐PZA突变体最终取代了敏感杆菌,但在无反应的C3HeB/FeJ小鼠中,它们从未超过总菌量的1%。C3HeB/FeJ小鼠大干酪样损伤中PZA的选择性无活性,最好的解释是液化干酪的中性pH值。

相似文献

1
Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum.
Antimicrob Agents Chemother. 2015 Nov 16;60(2):735-43. doi: 10.1128/AAC.01370-15. Print 2016 Feb.
2
Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.
Antimicrob Agents Chemother. 2015 Dec 7;60(2):1091-6. doi: 10.1128/AAC.02637-15. Print 2016 Feb.
3
Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis.
Dis Model Mech. 2015 Jun;8(6):603-10. doi: 10.1242/dmm.019513. Epub 2015 Mar 30.
4
High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis.
Antimicrob Agents Chemother. 2016 Jun 20;60(7):4197-205. doi: 10.1128/AAC.03085-15. Print 2016 Jul.
5
Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Infected C3HeB/FeJ Mice.
ACS Infect Dis. 2016 Apr 8;2(4):251-267. doi: 10.1021/acsinfecdis.5b00127. Epub 2016 Feb 24.
7
Fighting tuberculosis by drugs targeting nonreplicating bacilli.
Int J Mycobacteriol. 2017 Jul-Sep;6(3):213-221. doi: 10.4103/ijmy.ijmy_85_17.
8
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
Antimicrob Agents Chemother. 2012 Aug;56(8):4331-40. doi: 10.1128/AAC.00912-12. Epub 2012 Jun 4.
9
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions.
J Infect Dis. 2012 Feb 15;205(4):595-602. doi: 10.1093/infdis/jir786. Epub 2011 Dec 23.
10
Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0065822. doi: 10.1128/aac.00658-22. Epub 2022 Aug 4.

引用本文的文献

1
Essential Role of MHC II in the Antitubercular Efficacy of Pyrazinamide.
bioRxiv. 2025 Aug 21:2025.08.21.671522. doi: 10.1101/2025.08.21.671522.
2
Oxidative stress drives potent bactericidal activity of pyrazinamide against .
bioRxiv. 2024 Dec 18:2024.12.17.628853. doi: 10.1101/2024.12.17.628853.
4
Pyrazinoic acid, the active form of the anti-tuberculosis drug pyrazinamide, and aromatic carboxylic acid analogs are protonophores.
Front Mol Biosci. 2024 Feb 13;11:1350699. doi: 10.3389/fmolb.2024.1350699. eCollection 2024.
7
Mycobacterial Genetic Technologies for Probing the Host-Pathogen Microenvironment.
Infect Immun. 2023 Jun 15;91(6):e0043022. doi: 10.1128/iai.00430-22. Epub 2023 May 30.
9
Tools to develop antibiotic combinations that target drug tolerance in .
Front Cell Infect Microbiol. 2023 Jan 6;12:1085946. doi: 10.3389/fcimb.2022.1085946. eCollection 2022.
10
Efficacy of Replacing Linezolid with OTB-658 in Anti-Tuberculosis Regimens in Murine Models.
Antimicrob Agents Chemother. 2023 Feb 16;67(2):e0139922. doi: 10.1128/aac.01399-22. Epub 2023 Jan 9.

本文引用的文献

1
The association between sterilizing activity and drug distribution into tuberculosis lesions.
Nat Med. 2015 Oct;21(10):1223-7. doi: 10.1038/nm.3937. Epub 2015 Sep 7.
3
Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis.
Dis Model Mech. 2015 Jun;8(6):603-10. doi: 10.1242/dmm.019513. Epub 2015 Mar 30.
4
Nonclinical models for antituberculosis drug development: a landscape analysis.
J Infect Dis. 2015 Jun 15;211 Suppl 3:S83-95. doi: 10.1093/infdis/jiv183.
5
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses.
Immunol Rev. 2015 Mar;264(1):288-307. doi: 10.1111/imr.12252.
6
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Am J Respir Crit Care Med. 2015 Apr 15;191(8):943-53. doi: 10.1164/rccm.201410-1801OC.
7
Revisiting Anti-tuberculosis Activity of Pyrazinamide in Mice.
Mycobact Dis. 2014 May 5;4:145. doi: 10.4172/2161-1068.1000145.
8
Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study.
mBio. 2014 Oct 21;5(5):e01819-14. doi: 10.1128/mBio.01819-14.
9
10
Association between pncA gene mutations, pyrazinamidase activity, and pyrazinamide susceptibility testing in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2014 Aug;58(8):4928-30. doi: 10.1128/AAC.02394-14. Epub 2014 May 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验